TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: MRI Functional Connectivity of the visual pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Normalization of the albumin/creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Ability to manage daily activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Feasibility of recruiting patients into the study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of the intervention to patients randomized to the intervention arm
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of the protocol for patients randomized to the intervention arm
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients removed due to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in augmentation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in femoral artery delta blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in brachial artery flow mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for surgical intervention to stop bleeding
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Spontaneous EEG activity during labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall Best Confirmed Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of eligible families willing and able to be randomised
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concentration of Total Intratumoral Doxorubicin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheal Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in FACT-P Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: intrapatient correlation coefficient of MEP's
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain Scores on the Visual Analog Scale (VAS: 0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year cumulative incidence of recurrent HCC
Endpoint domain: Mortality/survival
Primary endpoint: Number of ventilator-free days at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: MTL subregion thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difficulties of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical and therapeutic approach to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change of ocular fundus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Textured novel object recognition test (NORT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical detection threshold (MDT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatosensory temporal discrimination threshold (STDT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAS-induced modulation of motor-evoked potentials (MEPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early detection of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gabapentin plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of the Thai version of the Calgary Depression Scale for Schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Validity of the Thai version of the Calgary Depression Scale for Schizophrenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in forced vital capacity (FVC) at 52 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of Sexual quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rest-activity Circadian rhythm (RAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting energetic expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimal rate of clinical responses
Endpoint domain: Adverse events/effects
Primary endpoint: 1-year efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset statuses of anemia, fluid retention, cardiac failure and hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Glycemic qualification rate in women with GDM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Numeric Rating Scale of Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of predicting sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR 20 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of abnormal development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Changing Glucose Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose Nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Primary Cancer diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of Adverse Events (AEs), Serious Adverse Events (SAEs) and Medical Events of Special Interests (MESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody formation against 40K PEG-rFIX and test for inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Renal oxygenation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Baseline Current Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final Current Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrimination of muscle invasive bladder cancer from non-muscle invasive bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Treatment Discontinuation (TTD)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Gross Motor Functional Measure - 66 Items (GMFM-66)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hop values for both legs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-interval from upfront surgery to adjuvant chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Skin Irritation Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in abdominal fat thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of closure patent ductus arteriosus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Experiencing 1 or More Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Complete Response (CR) + Very Good Partial Response (VGPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient reported symptom levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With at Least One Dose Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subject With Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma Concentration (Cmax) of BMS-986259 in Blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum concentration in plasma (Tmax) of BMS-986259 in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve over the dosing interval of BMS-986259 in blood serum - AUC(TAU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients presenting dose limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of HIV-specific PBMC (CD4/CD8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Major adverse cardiovascular and cerebrovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in symptoms associated with GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area under the concentration-time curve (AUC) for CYP and transporter probe substrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of nosocomial gastrointestinal infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of nosocomial upper respiratory tract infection (URTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Virus Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Fistula Needle Direction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Cannulation Method
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Fistula Needle Rotated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Arterial and Venous Needle Been on the Same Line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Measurement of patients after childbirth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants Free From Head Louse Infestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Paternal Attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sensibility and specificity of iPTH and serum calcium measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Physiological stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Change in score on the Druks and Masterson Naming Task
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Distance walked during six-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Remission Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants That Experience Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the Shannon Diversity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Neurologic Injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spiritual Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Operative field dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: recommended dose of PGT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: proportion of patients requiring platelet transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Fusion Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum number of symptom days in the previous two weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with an asthma related hospitalization, unscheduled clinic or emergency room visit for asthma in the previous month
Endpoint domain: Adverse events/effects
Primary endpoint: Level of Asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Constant Shoulder Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically relevant abnormal clinical laboratory parameters
Endpoint domain: Adverse events/effects
Primary endpoint: Percent change in total lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antihypertensive Medication Treatment Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication Adherence Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: End Tidal Carbon Dioxide measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion free from immunosuppression without biopsy proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Experiencing Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Doses (MTD) of Vemurafenib and Cobimetinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Cobimetinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Usability as measured by System Usability Scale (SUS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability as measured by User Experience Questionnaire (UEQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Lip Fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Calcinosis Activity Visual Analogue Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Complete Remission (CRc) Rate for Participants With R/R AML
Endpoint domain: Mortality/survival
Primary endpoint: Complete Remission + Bone Marrow Complete Remission + Partial Remission (CR + BM CR + PR) Rate for Participants With R/R Higher Risk MDS
Endpoint domain: Mortality/survival
Primary endpoint: Define the recommended Phase 2 dose (RP2D) of EOS884448
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pericarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time of Ten-meter walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success of same day yttrium Y-90 radioembolization planning and treatment angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients with renal impairment receiving transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recommended phase 2 dose of irinotecan hydrochloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of stage 2 and plus breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Local tumor progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline of morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increased lymph node sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adjusted Mean Change in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of completing nurse-driven telephone triage calls
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Responder Rate Analysis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative pain measured by visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Theoretical Endorsement of MIC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance of MIC medication recommendation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pathologic diagnosis of gallbladder polyp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of strain ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of symptoms of post-radial xerostomia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of excess weight lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intensity of platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Post-operative and Post-Discharge Nausea and Vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the rate of lung perfusion defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Patients' Adherence to Study Protocol
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of maternal weight gain per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Height growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lidocaine Maximum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bupivacaine Maximum Plasma Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coverage of therapeutic nutritional program
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants treated
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Local skin reaction scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Minimum Dietary Diversity in Complementary Feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment Responders Using Body Surface Area (BSA) at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Overt Aggression Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in capillary blood acid lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Range of wrist motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Psoriasis Area and Severity Index (PASI Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Logmar visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial Observed Plasma Drug Concentration (Co)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Plasma Concentration-Time Curve From Time 0 to Infinity (AUC-Infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Pregnancy After Breast Cancer
Endpoint domain: Life impact
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Post-Concussion Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: rate of complete molecular response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: antitumor efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prosthetics Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in QUALMS-score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in IPQ-score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing